Es­pe­ri­on shares surge af­ter ex­ecs say the FDA in­di­cates its LDL pill could be ready to roll in 2019

On Fri­day, an­a­lysts’ bleak as­sess­ment of Am­gen’s car­dio da­ta for its LDL fight­er Repatha caught Es­pe­ri­on’s shares in a broad at­tack that af­flict­ed sev­er­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA